Related Experiment Video
Updated: Aug 23, 2025
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone
Mengke Fan1,2, Guochuan Zhang2, Mingfang Xie2
1Department of Orthopedic Research Center, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Abstract:
The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the disease, the tendency toward malignant transformation remains. Therefore, it is important to identify new treatment methods for a GCTB. In this study, we first found high Siglec-15 expression in GCTB tissues, which was significantly associated with Campanacci staging and tumor recurrence. In Spearman's analysis, Siglec-15 expression was significantly correlated with Ki-67 levels in tumor tissues. In vitro, the mRNA and protein levels of Siglec-15 were high in GCTB stromal cells (Hs737. T), and Siglec-15 knockdown inhibited the biological characteristics of GCTB stromal cells. The RNA sequencing results enabled a prediction of the downstream genes by using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and MCODE analyses, and the findings showed that CXCL8 was significantly regulated by Siglec-15 and might be a promising downstream target gene of Siglec-15. Therefore, Siglec-15 may be a potential immunotherapy target for a GCTB.
Insights
High Siglec-15 expression in giant cell tumors of bone (GCTB) correlates with aggressive disease. Targeting Siglec-15 may offer a new immunotherapy approach for GCTB patients.
Area of Science:
- Oncology
- Immunology
- Bone Biology
Background:
- Giant cell tumor of bone (GCTB) is characterized by high recurrence rates and aggressive osteolysis, often leading to poor patient prognosis.
- Current treatments like scraping and resection are effective but do not eliminate the risk of malignant transformation.
- Novel therapeutic strategies are crucial for improving outcomes in GCTB patients.
Purpose of the Study:
- To investigate the role of Siglec-15 in GCTB pathogenesis.
- To identify potential therapeutic targets for GCTB treatment.
Main Methods:
- Analysis of Siglec-15 expression in GCTB tissues and correlation with clinical parameters (Campanacci staging, recurrence).
- In vitro studies using GCTB stromal cells (Hs737.T) to assess the functional impact of Siglec-15 knockdown.
- RNA sequencing followed by KEGG, GO, and MCODE analyses to identify downstream targets of Siglec-15.
Main Results:
- High Siglec-15 expression was observed in GCTB tissues and significantly associated with advanced Campanacci stage and tumor recurrence.
- Siglec-15 expression positively correlated with Ki-67 levels, a marker of cell proliferation.
- Siglec-15 knockdown in GCTB stromal cells inhibited their biological activity, and CXCL8 was identified as a key downstream target regulated by Siglec-15.
Conclusions:
- Siglec-15 is upregulated in GCTB and linked to aggressive tumor behavior.
- Siglec-15 plays a critical role in GCTB stromal cell biology.
- Siglec-15 and its downstream target CXCL8 represent promising targets for novel GCTB immunotherapies.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
